Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria

Cystic fibrosis (CF) pulmonary exacerbations (PEx) are broadly defined as episodes of increased signs and symptoms of worsening clinical status, including increased cough, sputum production, and decreased lung function [1 –3]. Increased airway mucus clearance and antibiotic therapy are the cornerstones of CF PEx treatment [4]. Antibiotic selection is typically guided by the results of recent bacterial cultures of airway samples, performed using media selective for species known to be prevalent and pathogenic in peo ple with CF (e.g., Staphylococcus aureus, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia spp., Achromobacter spp.) [4–6].

Source: Journal of Cystic Fibrosis - February 18, 2021 Category: Respiratory Medicine Authors: Lauren M. Castner, Madsen Zimbric, Shannon Cahalan, Corey Powell, Lindsay J. Caverly Tags: Original Article Source Type: research